Investor Relations

Neovasc, an OPKO Investee, Receives FDA Conditional Approval to Initiate TIARA-I Trial in U.S.: A Multinational, Multicenter Early Feasibility Trial of the TiaraTM Transcatheter Mitral Valve more »

OPKO Health Supports National Prostate Cancer Council Legislation more »

OPKO's Second Rayaldee Phase 3 Trial Meets Primary Endpoints more »

OPKO Launches the 4Kscore Test in Europe more »

Investor FAQs